

Product Update:

ciprofloxacin 3mg/mL + dexamethasone 1mg/mL ear drops (Cilodex®)
SMC No (1256/17)

Novartis Pharmaceuticals UK Ltd

09 June 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

ciprofloxacin+dexamethasone (Cilodex®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of the following infections in adults and children:

Acute otitis media in patients with tympanostomy tubes (AOMT)

Acute otitis externa

SMC restriction: Treatment of acute otitis media in patients with tympanostomy tubes (AOMT).

Cilodex® provides a licensed alternative to “off-label” use of ciprofloxacin and dexamethasone eye drops in the treatment of AOMT and is available at an equivalent cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 20 April 2017.

Chairman
Scottish Medicines Consortium